{
    "organizations": [],
    "uuid": "637823a492e7d0d5a67efcf7462b2095e2d2b399",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-rigel-pharmaceuticals-q1-loss-per/brief-rigel-pharmaceuticals-q1-loss-per-share-0-17-idUSASC09YPF",
    "ord_in_thread": 0,
    "title": "BRIEF-Rigel Pharmaceuticals Q1 Loss Per Share $0.17",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Rigel Pharmaceuticals Inc:\n* RIGEL ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE\n* Q1 LOSS PER SHARE $0.17 * Q1 EARNINGS PER SHARE VIEW $-0.18 â€” THOMSON REUTERS I/B/E/S\n* AS OF MARCH 31, HAD CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS OF $94.3 MILLION, VERSUS $115.8 MILLION AS OF DEC 31, 2017\n* RIGEL - EXPECTS CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS TO BE SUFFICIENT THROUGH AT LEAST NEXT 12 MONTHS Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-02T04:49:00.000+03:00",
    "crawled": "2018-05-02T15:47:14.047+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "rigel",
        "pharmaceutical",
        "inc",
        "rigel",
        "announces",
        "first",
        "quarter",
        "financial",
        "result",
        "provides",
        "company",
        "update",
        "q1",
        "loss",
        "per",
        "share",
        "q1",
        "earnings",
        "per",
        "share",
        "view",
        "thomson",
        "reuters",
        "march",
        "cash",
        "cash",
        "equivalent",
        "investment",
        "million",
        "versus",
        "million",
        "dec",
        "rigel",
        "expects",
        "cash",
        "cash",
        "equivalent",
        "investment",
        "sufficient",
        "least",
        "next",
        "month",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}